Screener
Novavax NVAX Support services — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Takeda licensing, royalties, and other revenue | ||||
| Licensing: | ||||
| Upfront fee(1) | — | $18,500 | — | $18,500 |
| Milestones | — | 3,434 | — | 3,434 |
| Royalties | (50) | 5,000 | 611 | 5,000 |
| Support services | 265 | 278 | 339 | 278 |
| Tota Total Takeda licensing, royalties, and other revenue | $215 | $27,212 | $950 | $27,212 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's support services — total revenue?
- Novavax (NVAX) reported support services — total revenue of $265K in Q2 2026.
- How has Novavax's support services — total revenue changed year-over-year?
- Novavax's support services — total revenue decreased by 4.7% year-over-year, from $278K to $265K.
- What does support services — total revenue mean?
- This metric represents the total gross revenue generated from specialized support services provided to third-party partners or collaborators. It reflects the financial contribution of service-based activities, such as technical assistance, manufacturing support, or collaborative research efforts, distinct from direct product sales. Monitoring this revenue stream helps investors assess the company's ability to monetize its technical expertise and infrastructure beyond its core vaccine product portfolio.
Ask your AI about Novavax's support services — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude